<DOC>
	<DOCNO>NCT00043121</DOCNO>
	<brief_summary>This phase I trial study side effect best dose capecitabine give together oxaliplatin , leucovorin calcium , fluorouracil treat patient advanced cancer metastatic remove surgery . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer That Metastatic Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish MTD toxicity profile oral capecitabine combination q 2 weekly intravenous oxaliplatin patient advanced malignancy . SECONDARY OBJECTIVES : I . To characterize pharmacokinetic parameter capecitabine recommend phase II dose combination capecitabine , oxaliplatin , 5-fluorouracil , leucovorin , well combination capecitabine oxaliplatin . II . To observe record antitumor activity . OUTLINE : This dose-escalation study capecitabine . Patients receive oxaliplatin IV 2 hour , leucovorin calcium IV , fluorouracil IV day 1 15 . Patients also receive oral capecitabine every 8 hour day 1-2 15-16 . Leucovorin calcium fluorouracil administration hold dose level 4 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patients must histologically cytologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective There limit prior therapy ECOG performance status 02 Leukocytes &gt; = 3,000/ul Absolute neutrophil count &gt; = 1,500/ul Platelets &gt; = 100,000/ul Total bilirubin = &lt; 1.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 x institutional upper limit normal Creatinine clearance &gt; = 50 mL/min calculate CockroftGault formula Patients &gt; = grade 2 ( Common Toxicity Criteria [ CTC ] 2.0 ) neuropathy Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Breastfeeding discontinue mother treat oxaliplatin Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week prior enter study Patients undergo therapy investigational agent Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic toxicity History allergy platinum compound antiemetic appropriate administration conjunction protocoldirected chemotherapy Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Pregnant nursing woman exclude study oxaliplatin DNA alkylating agent potential teratogenic abortifacient effect Human immunodeficiency virus ( HIV ) positive patient receive antiretroviral therapy ( HAART ) exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>